FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

GLAXO

1,520
-50.6 (-3.22%)
Updated 03:28 21/01 IST

GLAXO Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for GLAXO
Disclaimer
0% Bullish
0% Bearish

GLAXO Buy or Sell - Brokerage Reports

No. of reports in last year
2
No. of analysts
2
Average Consensus Forecast
1536
Consensus Potential
-4.90%
See GLAXO Share Price Targets >>

GLAXO Ratings

Long term GLAXO rating by FrontPage users
0/5 (0 Ratings)0
Find answers to all your questions on live GLAXO message board: Is GLAXO buy or sell? Should I buy GLAXO shares? Why are GLAXO shares falling? Should I invest in GLAXO stock?

  1. Home
  2. GLAXO Forum

GLAXO Share Price Discussion

N
Reputation: 10,343 • Jan 3 6:36 AM
Explained: Where does the world stand in the race for a coronavirus vaccine?
The following is what we know about the race to deliver vaccines to help end the coronavirus pandemic, which has killed more than 1.8 million people worldwide
The Economic Times
Like
Reply

GLAXOSMITHKLINE. Short term as well as for long term investors can keep adding this stock on every correction for tgt 1590-1635-1678+ positional tgt 1800-2000+ mark in days to come
Like
Reply
N
Reputation: 10,343 • Dec 15, 2020 4:11 AM
The next Covid vaccine challenge: Reassuring older Americans
The drugmakers Sanofi and GlaxoSmithKline said on Friday that their vaccine seemed not to work well in older people, because the dosage was too low to generate a sufficient immune response in that population.
The Economic Times
Like
Reply
N
Reputation: 10,343 • Dec 11, 2020 6:46 AM
Sanofi-GlaxoSmithKline's experimental Covid vaccine fails in some older patients
Instead, the companies said they planned to test a modified version of their vaccine in a smaller trial beginning in February. Rather than compare their candidate with a placebo, they said, it could be tested against a vaccine expected to be authorized by regulators for emergency use soon.
The Economic Times
Like
Reply
M
Reputation: 28,016 • Dec 4, 2020 3:52 AM

Type
Buy
Instrument
GLAXO
Entry Price
₹1,551.95
Price@Trade
₹1,550.9
Target Price
₹1,850
Stop Price
₹1,300
Valid Till
Jan 4, 2021 3:20 AM
Margin
₹387,987.5 approx for 250 Qty
Status
Validity Over
Exit Price
₹1,597.25
Net P&L
+₹11,325 (+2.92%)
Like
Reply (2)
See all replies
TrackerBot @trackerbot
Dec 4, 2020 3:53 AM

Update
Trade Entered
Entry Price
₹1,551.95
TrackerBot @trackerbot
Jan 4 8:50 AM

Update
Validity Over
Exit Price
₹1,597.25
Net P&L
+₹11,325 (+2.92%)
N
Reputation: 10,343 • Dec 2, 2020 4:56 AM
Markets like India added most to margins: Unilever
Unilever, at the Morgan Stanley Global Consumer and Retail virtual conference on Tuesday, said the minority view was that the company needed to reset its margin in order to improve the market share.
The Economic Times
Like
Reply

Type
Buy
Instrument
GLAXO
Entry Price
₹1,435
Price@Trade
₹1,442
Target Price
₹1,600  ₹1,800
Stop Price
₹1,350  ₹1,524
Valid Till
Dec 11, 2020 3:20 AM
Margin
₹100,450 approx for 70 Qty
Status
Stoploss Hit
Exit Price
₹1,524
Net P&L
+₹6,230 (+6.2%)
Like
Reply (7)
See all replies
SWING TRADERS @swingtraders
Nov 24, 2020 2:51 AM

Update
Stoploss Trailed
Price @ Update
₹1,531.65
Original SL
₹1,405
New SL
1524.0
SWING TRADERS @swingtraders
Nov 24, 2020 2:51 AM

Update
Target Extended
Price @ Update
₹1,533.35
Original Target
₹1,600
New Target
1800.0
TrackerBot @trackerbot
Nov 24, 2020 3:58 AM

Update
Stoploss Hit
Exit Price
₹1,524
N
Reputation: 10,343 • Nov 9, 2020 9:41 AM
Germany expects COVID-19 vaccine in Q1 2021 at the earliest
The German government will cover the cost of the vaccines, while the cost of setting up the vaccination centres will be borne by the states and public and private health insurers where appropriate.
The Economic Times
Like
Reply
N
Reputation: 10,343 • Oct 29, 2020 4:11 AM
Neutral on GSK Pharma, target price Rs 1410: Motilal Oswal
GlaxoSmithKline Pharmaceuticals Ltd., incorporated in the year 1924, is a Large Cap company (having a market cap of Rs 25389.73 Crore) operating in Pharmaceuticals sector.
The Economic Times
Like
Reply
N
Reputation: 10,343 • Oct 28, 2020 2:26 AM
GlaxoSmithKline Pharma Q2 results: Net profit declines 85% to Rs 76 cr
Consolidated revenue from operations of the company stood at Rs 879.32 crore for the quarter under consideration. It was Rs 882.02 crore for the same period a year ago, it added.
The Economic Times
Like
Reply
N
Reputation: 10,343 • Oct 28, 2020 2:13 AM
GlaxoSmithKline Pharma Q2 net profit declines 85% to Rs 76.47 crore
The company has recognised a financial impact of Rs 64.13 crore for the latest September quarter mainly to reflect the estimated realisable value of the assets, associated costs and impacts of reversal of provision on account of Zinetac recall, the filing said.
Moneycontrol
Like
Reply
N
Reputation: 10,343 • Oct 28, 2020 5:26 AM
GSK, Sanofi to make 200 mn doses available for COVID-19 vaccine alliance
COVAX aims to deliver 2 billion vaccine doses around the world by the end of 2021, and more than 180 nations have joined the plan. The United States and UK are leading a rush to strike deals with drugmakers to reserve supplies of experimental coronavirus vaccines.
The Economic Times
Like
Reply

Type
Sell
Instrument
GLAXO
Entry Price
₹1,556
Price@Trade
₹1,548.8
Target Price
₹1,420
Stop Price
₹1,560
Valid Till
Oct 15, 2020 3:20 AM
Margin
₹778,000 approx for 500 Qty
Status
Exited before entry
Like
Reply (1)
See all replies
Parvez Haleem @parvezhaleem
Oct 15, 2020 3:31 AM

Update
Exited before entry
Price @ Update
₹1,546.25
R
Reputation: 2,347 • Oct 8, 2020 1:00 AM

Centrum target on GLAXO
Date: 07-Oct-20 Broker: Centrum Price @ Call: 1594.25 Target: 1780 Potential: 0.12% Recommendation: BUY
Like
Reply
A
Reputation: -452 • Oct 7, 2020 3:31 AM

Type
Buy
Instrument
GLAXO
Entry Price
₹1,585
Price@Trade
₹1,585
Target Price
₹1,690
Stop Price
₹1,488
Valid Till
Oct 14, 2020 3:20 AM
Margin
₹79,250 approx for 50 Qty
Status
Exited
Exit Price
₹1,607
Net P&L
+₹1,100 (+1.39%)
Like
Reply (1)
See all replies
Akshay @akshayiyer
Oct 7, 2020 3:50 AM

Update
Exited
Exit Price
₹1,607
Net P&L
+₹1,100 (+1.39%)
N
Reputation: 10,343 • Oct 6, 2020 12:26 PM
GSK to widen COVID-19 antibody treatment trial after safety clearance
The long-acting single injection will be tested on recently diagnosed high-risk cases for its ability to prevent hospitalisation, typically a life threatening disease stage.
The Economic Times
Like
Reply

Type
Buy
Instrument
GLAXO
Entry Price
₹1,690  ₹1,688
Price@Trade
₹1,688.8
Target Price
₹1,706
Stop Price
₹1,680
Valid Till
Sep 10, 2020 3:20 AM
Margin
₹1,688 approx for 1 Qty
Status
Stoploss Hit
Exit Price
₹1,680
Net P&L
-₹8 (-0.47%)
Like
Reply (3)
See all replies
Market Stock @marketstock
Sep 10, 2020 5:30 AM

Update
Entry Price Modified
Price @ Update
₹1,688
Original Entry Price
₹1,690
New Entry Price
₹1,688
TrackerBot @trackerbot
Sep 10, 2020 5:31 AM

Update
Trade Entered
Entry Price
₹1,688
TrackerBot @trackerbot
Sep 10, 2020 5:38 AM

Update
Stoploss Hit
Exit Price
₹1,680
A
Reputation: 40,699 • Sep 9, 2020 4:42 AM

Type
Buy
Instrument
GLAXO
Entry Price
₹1,635
Price@Trade
₹1,635
Target Price
₹1,800
Stop Price
₹1,580
Valid Till
Sep 9, 2021 3:20 AM
Margin
₹408,750 approx for 250 Qty
Status
Exited
Exit Price
₹1,675.25
Net P&L
+₹10,062.5 (+2.46%)
Like
Reply (1)
See all replies
Alok Singh @Singhalok
Sep 11, 2020 3:53 AM

Update
Exited
Exit Price
₹1,675.25
Net P&L
+₹10,062.5 (+2.46%)

BUY #GLAXO Pharma
Above 1684-87
SL Paid only..
TARGET 1720-1735 Positional 3-5 days
Like
Reply

Type
Buy
Instrument
GLAXO
Entry Price
₹1,682
Price@Trade
₹1,673.05
Target Price
₹1,882
Stop Price
₹1,662
Valid Till
Oct 8, 2020 3:20 AM
Margin
₹1,682 approx for 1 Qty
Status
Stoploss Hit
Exit Price
₹1,662
Net P&L
-₹20 (-1.19%)
Like
Reply (2)
See all replies
TrackerBot @trackerbot
Sep 10, 2020 5:22 AM

Update
Trade Entered
Entry Price
₹1,682
TrackerBot @trackerbot
Sep 11, 2020 5:00 AM

Update
Stoploss Hit
Exit Price
₹1,662
N
Reputation: 10,343 • Sep 7, 2020 6:56 AM
Stock market update: MidCap stocks down; Future Retail drops 5%
The BSE MidCap index was trading 0.78 per cent down at 14701.63.
The Economic Times
Like
Reply
N
Reputation: 10,343 • Aug 25, 2020 7:01 AM
Stock market update: MidCap stocks advance; Max Fin Serv soars 14%
The BSE MidCap index was trading 0.5 per cent up at 15093.71.
The Economic Times
Like
Reply

Type
Buy
Instrument
GLAXO
Entry Price
₹1,484
Price@Trade
₹1,485
Target Price
₹1,590
Stop Price
₹1,410
Valid Till
Sep 21, 2020 3:20 AM
Margin
₹22,260 approx for 15 Qty
Status
Expired before entry
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Sep 21, 2020 8:50 AM

Update
Expired before entry
Price @ Update
₹1,699.85
N
Reputation: 10,343 • Aug 13, 2020 7:41 AM
US tariffs weigh on Europe stocks; Airbus dips
The pan-European STOXX 600 was down 0.4%, with Airbus sliding 0.7% after Washington said it would maintain 15% tariffs on the planes and 25% tariffs on other European goods.
The Economic Times
Like
Reply
N
Reputation: 10,343 • Aug 12, 2020 4:26 AM
U.S. inks $1.5 billion deal with Moderna for 100 million doses of COVID-19 vaccine
The United States in recent weeks has made deals to acquire hundreds of millions of doses of potential COVID-19 vaccines from several companies as part of its Operation Warp Speed program, which aims to deliver a vaccine in the country by the end of the year.
The Economic Times
Like
Reply
N
Reputation: 10,343 • Aug 2, 2020 6:41 AM
When it comes to a coronavirus vaccine, rich nations are first in line
Although international groups and a number of nations are promising to make vaccines affordable and accessible to all, doses will likely struggle to keep up with demand in a world of roughly 7.8 billion people. The possibility wealthier countries will monopolize supply, a scenario that played out in the 2009 swine flu pandemic, has fueled concerns among poor nations and health advocates.
The Economic Times
Like
Reply
N
Reputation: 10,343 • Jul 29, 2020 1:43 AM
GlaxoSmithKline Pharmaceuticals Q1 net profit declines 2.38% to Rs 111 crore
The company had posted a net profit of Rs 113.54 crore in the corresponding period previous fiscal, GlaxoSmithKline Pharmaceuticals said in a BSE filing.
Moneycontrol
Like
Reply
N
Reputation: 10,343 • Jul 29, 2020 1:36 AM
Board Meetings Today: Maruti Suzuki, Bharti Airtel, SpiceJet, Dr Reddy’s Labs and Ceat
GSK Pharma, Mahindra Lifespace, Manappuram Finance and TVS Motor will announce June quarter earnings today.
The Economic Times
Like
Reply
N
Reputation: 10,343 • Jul 23, 2020 11:31 AM
'Strict lockdowns' hit FMCG major Unilever's growth in India, other key markets
Anglo-Dutch FMCG major Unilever on Thursday said strict lockdowns in key markets, including India, have impacted its business growth in the first half of 2020.
The Economic Times
Like
Reply
N
Reputation: 10,343 • Jul 17, 2020 4:31 AM
European Union in talks with Moderna, BioNtech, CureVac to secure Covid-19 vaccines
The talks follow a deal reached in June by four EU states with AstraZeneca for the upfront purchase of 400 million doses of its potential Covid-19 vaccine, in principle available to all 27 EU nations. The information on the ongoing talks was shared by the European Commission, the EU executive arm, with EU health ministers at a meeting in Berlin on Thursday.
The Economic Times
Like
Reply
N
Reputation: 10,343 • Jul 10, 2020 11:03 AM
Indian pharma market contracts nearly 6% in Q1FY21
Chronic segment that includes drugs for cardiovascular, diabetes, and neuro saw a slump in sales in Q1FY21 due to pre-emptive buying in March
Moneycontrol
Like
Reply
N
Reputation: 10,343 • Jun 29, 2020 4:03 AM
Immunity booster for your portfolio! Here's a list of 10 stocks to get through COVID times
India's long-term fundamental stories for discretionary and consumption are intact, and sectors such as IT, Pharmaceuticals, Bank, Cement, Gas, Capital Goods, and insurance are expected to be the new leaders.
Moneycontrol
Like
Reply
N
Reputation: 10,343 • Jun 11, 2020 10:43 AM
GSK is world's largest vaccine maker. Yet it has been tame with its COVID-19 strategy
GSK is betting on its adjuvant technology to support companies developing COVID-19 vaccines.
Moneycontrol
Like
Reply
R
Reputation: 2,347 • May 21, 2020 9:00 AM

Karvy Stock Broking target on GLAXO
Date: 19-May-20 Broker: Karvy Stock Broking Price @ Call: 1390.74 Target: 1292 Recommendation: SELL
Like
Reply

*Result Highlight*
Glaxosmithkline Pharmaceuticals Ltd. Q4 Cons: Net profit down -6% at Rs. 138.07 cr. Vs Rs. 146.81 cr. (YoY) and Revenue up 3.3% at Rs. 775.8 cr. Vs Rs. 750.81 cr. (YoY)
Board of Directors recommend a Dividend of Rs 40 per equity share of face value of Rs.10 eac...
Read more...
3
Reply
N
Reputation: 10,343 • May 18, 2020 2:18 AM
GlaxoSmithKline Pharma Q4 net profit declines 6% to Rs 138 crore
For the fiscal year ended March this year, the company posted a net profit of Rs 93.20 crore as against Rs 445.39 crore in the previous fiscal, the filing said.
Moneycontrol
Like
Reply
N
Reputation: 10,343 • May 18, 2020 2:08 AM
Trade Setup for Tuesday: Top 15 things to know before Opening Bell
Key support level for Nifty is placed at 8,700.57, followed by 8,577.88. If the index moves up, key resistance levels to watch out for are 9,052.12 and 9,280.98.
Moneycontrol
Like
Reply
K
Reputation: -34,724 • May 6, 2020 11:06 AM

Sources :
Glaxo to sell HUL shares via Block deals tomorrow
Deal likely at Rs 1850-1950 per share
Glaxo to sell nearly 6% stake in HUL
Glaxo looks to raise over Rs 25,000 crores via HUL block deal
Like
Reply (3)
See all replies
Rockstar19 @TST007
May 6, 2020 1:25 AM

Yes sir so tomorrow its a red for HUL
King999 @king999
May 6, 2020 1:44 AM

everyday is red for HUL HAHAHA
Rockstar19 @TST007
May 7, 2020 5:39 AM

😂😂😂
N
Reputation: 10,343 • May 5, 2020 12:58 PM
Hot Stocks | Glaxo Pharma, M&M, Tata Comm three buy ideas for short term
In the week gone by, Nifty took out the crucial resistance of 9,390, which will interchange its role as immediate resistance.
Moneycontrol
Like
Reply
N
Reputation: 10,343 • Apr 15, 2020 12:38 PM
Hot Stocks | Three stock ideas for the short term
By surpassing the resistance of 8,600 in the previous week, Nifty also confirmed the bullish inverse head and shoulder pattern breakout on the daily line charts.
Moneycontrol
Like
Reply
N
Reputation: 10,343 • Apr 12, 2020 6:33 AM
USFDA asks companies to remove ranitidine products; will Indian regulator review its stand?
The USFDA is investigating presence N-Nitrosodimethylamine, a probable cancer causing impurity in ranitidine products.
Moneycontrol
Like
Reply
GLAXO

Type
Buy
Instrument
GLAXO
Entry Price
₹1,198
Price@Trade
₹1,198
Target Price
₹1,280
Stop Price
₹1,150
Valid Till
Apr 16, 2020 3:20 AM
Margin
₹1,198 approx for 1 Qty
Status
Exited
Exit Price
₹1,242.85
Net P&L
+₹44.81 (+3.74%)
Like
Reply (1)
See all replies

Update
Exited
Exit Price
₹1,242.85
Net P&L
+₹44.81 (+3.74%)
N
Reputation: 10,343 • Mar 19, 2020 10:18 AM
Coronavirus pandemic | Pharma companies ask sales representatives to work from home
India's largest drug maker Sun Pharma which has field force 9,500 plus covering over 400,000 doctors in every nook and corner of the country said it is encouraging employees in the field globally to work from home.
Moneycontrol
Like
Reply
N
Reputation: 10,343 • Mar 9, 2020 2:23 AM
Pharma sales see rebound in February on back of respiratory drugs
Eight of the top 10 therapies registered a growth of more than 10 percent.
Moneycontrol
Like
Reply
N
Reputation: 10,343 • Mar 5, 2020 3:43 AM
24 companies in BSE500 index reported net loss in Q3; what should you do with the stocks?
Among the top 500 companies, over 20 companies turned loss-making in the December quarter, data from AceEquity showed
Moneycontrol
Like
Reply
N
Reputation: 10,343 • Mar 4, 2020 11:18 AM
MNC drug body OPPI names Sharad Tyagi as President
Tyagi is currently Managing Director, Boehringer Ingelheim India. He replaces A Vaidheesh of GSK.
Moneycontrol
Like
Reply
N
Reputation: 10,343 • Mar 4, 2020 9:03 AM
Sridhar Venkatesh appointed as GSK India MD, VP
Venkatesh has more than 24 years of diverse experience in pharmaceuticals and healthcare, and has a strong track record of success in multiple roles within GSK, it added.
Moneycontrol
Like
Reply
N
Reputation: 10,343 • Feb 10, 2020 12:28 PM
Ranitidine recall forces GSK to alter Indian market strategy
GSK had initiated global voluntary recall of Ranitidine in September 2019, following reports of a probable cancer causing impurity called N‐nitrosodimethylamine (NDMA).
Moneycontrol
Like
Reply
GSK announces sale of Vemagal plant; takes Rs 640 crore hit on account of Zinetac recall - Times of India
Times of India brings the Latest & Top Breaking News on Politics and Current Affairs in India & around the World, Cricket, Sports, Business, Bollywood News and Entertainment, Science, Technology, Health & Fitness news & opinions from leading columnists.
The Times of India

Bad News for Pharmaceutical sector GlaxoSmithKline (GSK) Pharma - Bangalore
Yesterday night gave a very big Dinner in 5 star hotel to all Bangalore Employee & at the end of Dinner
GSK handed Termination Letter. With 6 months Salary Cheque.
GSK Pharma - Bangalore plant is clos...
Read more...
Like
Reply
GLAXO

Type
Sell
Instrument
GLAXO
Entry Price
₹1,362
Price@Trade
₹1,372.9
Target Price
₹1,330
Stop Price
₹1,388  ₹1,353
Valid Till
Feb 7, 2020 3:20 AM
Margin
₹1,362 approx for 1 Qty
Status
Exited
Exit Price
₹1,335.95
Net P&L
+₹26.01 (+1.91%)
Like
Reply (3)
See all replies
TrackerBot @trackerbot
Feb 6, 2020 4:53 AM

Update
Trade Entered
Entry Price
₹1,362
JJ Technicals @jjtechnicals
Feb 6, 2020 5:51 AM

Update
Stoploss Trailed
Price @ Update
₹1,342
Original SL
₹1,388
New SL
₹1,353
JJ Technicals @jjtechnicals
Feb 6, 2020 5:55 AM

Update
Exited
Exit Price
₹1,335.95
Net P&L
+₹26.01 (+1.91%)
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • GLAXO - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization22,020.76
    Enterprise Value20,865.43
    Price to Earnings50.18
    Price to Book Value10.28
    Return on Capital Employed0.26
    Return on Equity0.17
    Face Value10
    Dividend Yield0.02
  • GLAXO - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    7-Oct-20CentrumBuy1,780
    19-May-20Karvy Stock BrokingSell1,292
    21-May-19Motilal OswalNeutral1,350
    23-Oct-18CentrumSell950
    26-Jul-18CentrumSell950
    GLAXO Brokerage Price Target
  • GLAXO Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jan 2115701578.515151519.5
    Jan 20154015891538.051570.6
    Jan 191560156015301541.15
    Jan 181519.3154014951530.5
    Jan 1515251530.515001519.3
  • GLAXO Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹1,569.64
    30 Day Moving Average₹1,565.11
    50 Day Moving Average₹1,538.75
    100 Day Moving Average₹1,553.68
    200 Day Moving Average₹1,492.18
  • GLAXO - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue2,895.882,994.51-0.03
    Operating Profit508.44417.50.22
    Profit Before Tax541.58511.080.06
    Net Income351.99336.780.05
  • GLAXO - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds2,1422,079.950.03
    Total Liabilities1,7671,901.27-0.07
    Total Assets3,9093,981.22-0.02
  • GLAXO - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity474.77233.131.04
    Cash from Investing Activity-107.01303.24-1.35
    Cash from Financing Activity-306.63-510.76-0.4
    Net Cash Flow61.1225.611.39
  • GLAXO - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.090.11
    Return on Equity0.170.17
    Return on Capital Employed0.260.25
  • GLAXO - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.12
    3 Year CAGR Growth in Operating Profit-0.12
    3 Year CAGR Growth in EBIDTA-0.25
    3 Year CAGR Growth in Net Income-0.25
    3 Yr CAGR Growth - Diluted EPS-0.25
  • GLAXO - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.1
    5 Year CAGR Growth in Operating Profit-0.24
    5 Year CAGR Growth in EBIDTA-0.33
    5 Year CAGR Growth in Net Income-0.39
    3 Yr CAGR Growth - Diluted EPS-0.39
  • GLAXO - Recent News

    keyboard_arrow_down
    NewsBot
    Dec 15, 2020 4:11 AM
    The next Covid vaccine challenge: Reassuring older Americans
    The Economic Times
    NewsBot
    Dec 11, 2020 6:46 AM
    Sanofi-GlaxoSmithKline's experimental Covid vaccine fails in some older patients
    The Economic Times
    NewsBot
    Dec 2, 2020 4:56 AM
    Markets like India added most to margins: Unilever
    The Economic Times
    NewsBot
    Oct 29, 2020 4:11 AM
    Neutral on GSK Pharma, target price Rs 1410: Motilal Oswal
    The Economic Times
    NewsBot
    Oct 28, 2020 2:26 AM
    GlaxoSmithKline Pharma Q2 results: Net profit declines 85% to Rs 76 cr
    The Economic Times
    NewsBot
    Oct 28, 2020 5:26 AM
    GSK, Sanofi to make 200 mn doses available for COVID-19 vaccine alliance
    The Economic Times
    NewsBot
    Sep 7, 2020 6:56 AM
    Stock market update: MidCap stocks down; Future Retail drops 5%
    The Economic Times
    NewsBot
    Jul 29, 2020 1:36 AM
    Board Meetings Today: Maruti Suzuki, Bharti Airtel, SpiceJet, Dr Reddy’s Labs and Ceat
    The Economic Times
    NewsBot
    Jul 23, 2020 11:31 AM
    'Strict lockdowns' hit FMCG major Unilever's growth in India, other key markets
    The Economic Times
    NewsBot
    May 5, 2020 12:58 PM
    Hot Stocks | Glaxo Pharma, M&M, Tata Comm three buy ideas for short term
    Moneycontrol
  • GLAXO - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020